The World Health Organization and St. Jude Children’s Research Hospital Dec. 13 announced plans to establish the Global Platform for Access to Childhood Cancer Medicines to provide an uninterrupted supply of quality-assured childhood cancer medicines to low- and middle-income countries.
To accurately gauge the impact of the National Cancer Act of 1971 at the half-century point, Abbe R. Gluck and Charles S. Fuchs decided to focus on more than the science of cancer.
Spotlight article Video: Nixon National Cancer Conference Kicks OffBy Richard Nixon Foundation | Dec. 8, 2021 On Dec. 23, 1971, in the East Room of the White House, describing it as something akin to a Christmas gift to the American people, President Richard Nixon signed the National Cancer Act of 1971. “We are here today […]
Soon after starting work on a book about the role the NCI-designated cancer centers have played in the National Cancer Program, Skip Trump and Eric Rosenthal got in touch with John W. Yarbro.
David S. Fischer, clinical professor of medicine (oncology) at Yale School of Medicine and attending physician at Smilow Cancer Hospital at Yale, authored this history of the Clinical Cancer Program at Yale in 2012.
The National Coalition for Cancer Survivorship began in 1986 with 23 people at a hotel in Albuquerque and a $100 contribution from Patricia A. Ganz, who recalls thinking: “I don’t think I’ve ever invested in anything that was so good.”
The Richard Nixon Foundation will host the Nixon National Cancer Conference at the Richard Nixon Presidential Library and Museum in Yorba Linda, CA, on Dec. 1-2.
FDA watchers and clinical trialists in oncology may want to pay close attention to the agency’s latest plans to increase representation of traditionally marginalized populations in drug development.
There’s a cultural perception in drug development that enrolling a diverse, heterogeneous patient cohort can be “risky” for detecting drug effects—a perception that needs to go away, said Lola Fashoyin-Aje, associate director of the Science & Policy Program to Address Disparities at the FDA’s Oncology Center of Excellence and a deputy division director in the agency’s Office of Oncologic Diseases.
Drug manufacturers and researchers have a moral obligation to design clinical trials that adequately represent the target population for the investigational agent—and these medical products need to be safe and effective for everyone, leading clinical trial experts in oncology say.
